CVS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CVS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CVS Health's change in receivables for the quarter that ended in Dec. 2023 was $-2,340 Mil. It means CVS Health's Accounts Receivable increased by $2,340 Mil from Sep. 2023 to Dec. 2023 .
CVS Health's change in receivables for the fiscal year that ended in Dec. 2023 was $-6,260 Mil. It means CVS Health's Accounts Receivable increased by $6,260 Mil from Dec. 2022 to Dec. 2023 .
CVS Health's Accounts Receivable for the quarter that ended in Dec. 2023 was $11,908 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. CVS Health's Days Sales Outstanding for the three months ended in Dec. 2023 was 11.58.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CVS Health's liquidation value for the three months ended in Dec. 2023 was $-143,694 Mil.
The historical data trend for CVS Health's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Health Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial |
![]() |
![]() |
-2,158.00 | -1,510.00 | -2,703.00 | -2,971.00 | -6,260.00 |
CVS Health Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Change In Receivables | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-962.00 | -751.00 | -53.00 | -3,116.00 | -2,340.00 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6,260 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVS Health (NYSE:CVS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
CVS Health's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 11908 | / | 93813 | * | 91 |
= | 11.58 |
2. In Ben Graham's calculation of liquidation value, CVS Health's accounts receivable are only considered to be worth 75% of book value:
CVS Health's liquidation value for the quarter that ended in Dec. 2023 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 11455 | - | 173092 | + | 0.75 * 11908 | + | 0.5 * 18025 |
= | -143,694 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CVS Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Edward J Ludwig | director | C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417 |
Michael F Mahoney | director | BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Thomas F. Cowhey | officer: SVP, Interim CFO | 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027 |
J Scott Kirby | director | 233 S. WACKER DRIVE 11TH FL WHQLD, CHICAGO IL 60606 |
Brian A Kane | officer: EVP/President, Aetna | 500 W MAIN STREET, LOUISVILLE KY 40202 |
James David Clark | officer: SVP, Cont & Chief Acct Officer | ONE CVS DRIVE, WOONSOCKET RI 02760 |
Karen S Lynch | officer: EVP & Pres, Aetna Bus Unit | 151 FARMINGTON AVENUE, RW61, HARTFORD CT 06156 |
Samrat S. Khichi | officer: EVP, CPO and General Counsel | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Thomas M Moriarty | officer: EVP & General Counsel | 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417 |
Jeffrey R. Balser | director | 3657 RICHLAND AVE., NASHVILLE TN 37205 |
Alan Lotvin | officer: EVP, Transformation | 55 NOD ROAD, AVON CT 06001 |
Daniel P Finke | officer: EVP/Pres, Health Care Benefits | ONE CVS DRIVE, WOONSOCKET RI 02895 |
Tilak Mandadi | officer: EVP, Chief Technology Officer | 3600 LAS VEGAS BLVD. SOUTH, LAS VEGAS NV 89109 |
Sreekanth K Chaguturu | officer: EVP and Chief Medical Officer | ONE CVS DRIVE, WOONSOCKET RI 02895 |
Prem S Shah | officer: EVP and Co-President of Retail | ONE CVS DRIVE, WOONSOCKET RI 02895 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.